Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD
- PMID: 12424709
- PMCID: PMC378588
- DOI: 10.1086/344579
Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD
Abstract
We studied 11 new kindreds with primary pigmented nodular adrenocortical disease (PPNAD) or Carney complex (CNC) and found that 82% of the kindreds had PRKAR1A gene defects (including seven novel inactivating mutations), most of which led to nonsense mRNA and, thus, were not expressed in patients' cells. However, a previously undescribed base substitution in intron 6 (exon 6 IVS +1G-->T) led to exon 6 skipping and an expressed shorter PRKAR1A protein. The mutant protein was present in patients' leukocytes and tumors, and in vitro studies indicated that the mutant PRKAR1A activated cAMP-dependent protein kinase A (PKA) signaling at the nuclear level. This is the first demonstration of an inactivating PRKAR1A mutation being expressed at the protein level and leading to stimulation of the PKA pathway in CNC patients. Along with the lack of allelic loss at the PRKAR1A locus in most of the tumors from this kindred, these data suggest that alteration of PRKAR1A function (not only its complete loss) is sufficient for augmenting PKA activity leading to tumorigenesis in tissues affected by CNC.
Figures





Similar articles
-
Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit (PRKAR1A) in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas" (Carney complex).Ann N Y Acad Sci. 2002 Jun;968:3-21. doi: 10.1111/j.1749-6632.2002.tb04323.x. Ann N Y Acad Sci. 2002. PMID: 12119264 Review.
-
PRKAR1A mutations in primary pigmented nodular adrenocortical disease.Pituitary. 2006;9(3):211-9. doi: 10.1007/s11102-006-0266-1. Pituitary. 2006. PMID: 17036196 Review.
-
A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds.J Clin Endocrinol Metab. 2006 May;91(5):1943-9. doi: 10.1210/jc.2005-2708. Epub 2006 Feb 7. J Clin Endocrinol Metab. 2006. PMID: 16464939
-
A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer.J Clin Endocrinol Metab. 2012 Feb;97(2):351-9. doi: 10.1210/jc.2011-2244. Epub 2011 Nov 23. J Clin Endocrinol Metab. 2012. PMID: 22112814 Free PMC article.
-
Human tumors associated with Carney complex and germline PRKAR1A mutations: a protein kinase A disease!FEBS Lett. 2003 Jul 3;546(1):59-64. doi: 10.1016/s0014-5793(03)00452-6. FEBS Lett. 2003. PMID: 12829237 Review.
Cited by
-
Carney complex (CNC).Orphanet J Rare Dis. 2006 Jun 6;1:21. doi: 10.1186/1750-1172-1-21. Orphanet J Rare Dis. 2006. PMID: 16756677 Free PMC article. Review.
-
The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits.J Clin Endocrinol Metab. 2009 Jul;94(7):2406-13. doi: 10.1210/jc.2009-0031. Epub 2009 Apr 21. J Clin Endocrinol Metab. 2009. PMID: 19383776 Free PMC article.
-
Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.Curr Opin Pharmacol. 2011 Dec;11(6):689-97. doi: 10.1016/j.coph.2011.10.003. Epub 2011 Oct 31. Curr Opin Pharmacol. 2011. PMID: 22047791 Free PMC article. Review.
-
A genetic and molecular update on adrenocortical causes of Cushing syndrome.Nat Rev Endocrinol. 2016 May;12(5):255-62. doi: 10.1038/nrendo.2016.24. Epub 2016 Mar 11. Nat Rev Endocrinol. 2016. PMID: 26965378 Review.
-
cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.Mol Cell Endocrinol. 2013 May 22;371(1-2):208-20. doi: 10.1016/j.mce.2013.01.015. Epub 2013 Feb 26. Mol Cell Endocrinol. 2013. PMID: 23485729 Free PMC article. Review.
References
Electronic-Database Information
-
- Genome Database, http://gdbwww.gdb.org/ (for sequence information)
-
- Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/omim/ (for CNC [MIM 160980]) - PubMed
-
- Whitehead Institute/MIT, Center for Genome Research,http://www.genome.wi.mit.edu/ (for sequence information)
References
-
- Bertherat J, Chanson P, Montminy M (1995) The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9:777–783 - PubMed
-
- Carney JA (1990) Psammomatous melanotic schwannoma: a distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome. Am J Surg Pathol 14:206–222 - PubMed
-
- Carney JA, Boccon-Gibod L, Jarka DE, Tanaka Y, Swee RG, Unni KK, Stratakis CA (2001) Osteochondromyxoma of bone: a congenital tumor associated with lentigines and other unusual disorders. Am J Surg Pathol 25:164–176 - PubMed
-
- Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL (1985) The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine 64:270–283 - PubMed
-
- Carney JA, Hruska LS, Beauchamp GD, Gordon H (1986) Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 61:165–172 - PubMed
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases